Regen Biopharma pays down $1.02M of convertible notes, principal now $1.34M

Regen BioPharma Inc

Principal indebtedness on convertible notes reduced from $2,364,075 (Jun 30) to $1,340,621 (Dec 13, 2021).
Company satisfied $1,023,454 of principal debt between July 1 and Dec 13, 2021.
This represents a 43% reduction in principal debt over approximately 5.5 months.

item 8.01

Regen BioPharma Inc filing history →

Source: SEC EDGAR

accession 0001607062-21-000626

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.